Thompson DC - Search Results

1

A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models.

Mbalaviele G, Sommers CD, Bonar SL, Mathialagan S, Schindler JF, Guzova JA, Shaffer AF, Melton MA, Christine LJ, Tripp CS, Chiang PC, Thompson DC, Hu Y, Kishore N. Mbalaviele G, et al. Among authors: thompson dc. J Pharmacol Exp Ther. 2009 Apr;329(1):14-25. doi: 10.1124/jpet.108.143800. Epub 2009 Jan 23. J Pharmacol Exp Ther. 2009. PMID: 19168710

2

Combined use of pharmacokinetic modeling and a steady-state delivery approach allows early assessment of IkappaB kinase-2 (IKK-2) target safety and efficacy.

Chiang PC, Kishore NN, Thompson DC. Chiang PC, et al. Among authors: thompson dc. J Pharm Sci. 2010 Mar;99(3):1278-87. doi: 10.1002/jps.21909. J Pharm Sci. 2010. PMID: 19743500

3

Evaluating the suitability of using rat models for preclinical efficacy and side effects with inhaled corticosteroids nanosuspension formulations.

Chiang PC, Hu Y, Blom JD, Thompson DC. Chiang PC, et al. Among authors: thompson dc. Nanoscale Res Lett. 2010 Apr 10;5(6):1010-9. doi: 10.1007/s11671-010-9597-y. Nanoscale Res Lett. 2010. PMID: 20672144 Free PMC article.

4

A formulation-enabled preclinical efficacy assessment of a farnesoid X receptor agonist, GW4064, in hamsters and cynomolgus monkeys.

Chiang PC, Thompson DC, Ghosh S, Heitmeier MR. Chiang PC, et al. Among authors: thompson dc. J Pharm Sci. 2011 Nov;100(11):4722-33. doi: 10.1002/jps.22664. Epub 2011 Jun 9. J Pharm Sci. 2011. PMID: 21660973

5

Utilizing a novel tandem oral dosing strategy to enhance exposure of low-solubility drug candidates in a preclinical setting.

Chiang PC, South SA, Foster KA, Daniels JS, Wene SP, Albin LA, Thompson DC. Chiang PC, et al. Among authors: thompson dc. J Pharm Sci. 2010 Jul;99(7):3132-40. doi: 10.1002/jps.22092. J Pharm Sci. 2010. PMID: 20229600

6

Novel metabolic bioactivation mechanism for a series of anti-inflammatory agents (2,5-diaminothiophene derivatives) mediated by cytochrome p450 enzymes.

Hu Y, Yang S, Shilliday FB, Heyde BR, Mandrell KM, Robins RH, Xie J, Reding MT, Lai Y, Thompson DC. Hu Y, et al. Among authors: thompson dc. Drug Metab Dispos. 2010 Sep;38(9):1522-31. doi: 10.1124/dmd.110.032581. Epub 2010 Jun 7. Drug Metab Dispos. 2010. PMID: 20530221

7

Evaluation of two novel peptide safety markers for exocrine pancreatic toxicity.

Walgren JL, Mitchell MD, Whiteley LO, Thompson DC. Walgren JL, et al. Among authors: thompson dc. Toxicol Sci. 2007 Mar;96(1):184-93. doi: 10.1093/toxsci/kfl190. Epub 2006 Dec 14. Toxicol Sci. 2007. PMID: 17169977

8

Identification of novel peptide safety markers for exocrine pancreatic toxicity induced by cyanohydroxybutene.

Walgren JL, Mitchell MD, Whiteley LO, Thompson DC. Walgren JL, et al. Among authors: thompson dc. Toxicol Sci. 2007 Mar;96(1):174-83. doi: 10.1093/toxsci/kfl189. Epub 2006 Dec 14. Toxicol Sci. 2007. PMID: 17169978

9

Proteomics: recent applications and new technologies.

Elrick MM, Walgren JL, Mitchell MD, Thompson DC. Elrick MM, et al. Among authors: thompson dc. Basic Clin Pharmacol Toxicol. 2006 May;98(5):432-41. doi: 10.1111/j.1742-7843.2006.pto_391.x. Basic Clin Pharmacol Toxicol. 2006. PMID: 16635100 Free article. Review.

10

Application of proteomic technologies in the drug development process.

Walgren JL, Thompson DC. Walgren JL, et al. Among authors: thompson dc. Toxicol Lett. 2004 Apr 1;149(1-3):377-85. doi: 10.1016/j.toxlet.2003.12.047. Toxicol Lett. 2004. PMID: 15093284 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

259 results

Search Page